Capella | Science
15338
page,page-id-15338,page-template,page-template-full_width,page-template-full_width-php,ajax_fade,page_not_loaded,,qode-theme-ver-9.4.1,wpb-js-composer js-comp-ver-4.12,vc_responsive
 

Science

Banner_06

Early Stage Pipeline

We are developing a strong portfolio of mAbs in oncology and autoimmune disease. Our most advanced assets will enter preclinical development in 2015.

Partnering

Capella BioScience discovers and develops mAbs both independently and in collaboration with biotechnology and academic partners.

We are employing our proprietary technologies to discover, develop and commercialise monoclonal antibody medicines to difficult and novel drug targets.

Partnering

If you would like to find out more about Capella BioScience, please get in touch.